Lepro Pharma Compass Opc Private Limited - Due diligence report

A 360° intelligence report on Pharmacompass: trust score, financial health, credit view, compliance, directors, growth and distress signals …

2014-09-01 New Delhi, Delhi Active Unlisted Active Compliant
Share
LP Lepro Pharma Compass Opc Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pharmacompass — 360° Intelligence Report

Generated from MCA filings & public records
84/100
Trust Score
Low Risk

Pharmacompass is assessed as Low Risk with a Trust Score of 84/100. Pharmacompass is an active company incorporated in 2014, operating in the Internet sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Lepro Pharma Compass Opc Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
NIDHI MEHTA 01234567 Director 01/04/2018 6 yrs Approved
Deepak Pradhan 01234567 Director 01/04/2018 6 yrs Approved
Sanjay Gandhi 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2020)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 11+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view70/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 9 events
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Sep 2023
Last AGM held
Annual general meeting
30 Nov 2021
Director ceased
Deepak Pradhan
Director ceased
Sanjay Gandhi
11 Sep 2021
Director appointed
Deepak Pradhan (Director)
Director appointed
Sanjay Gandhi (Director)
Director ceased
BHARAT MEHTA
01 Sep 2014
Incorporated
Registered with Roc Delhi
Director appointed
NIDHI MEHTA (Nominee)
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Medisphere Life Sciences Private Limited U24232TG2009PTC065711 Hyderabad, Telangana, India
Daewoong Pharmaceutical U24232TG2012FTC084511 Hyderabad, Telangana, India
Shivika Cosmeceuticals India Private Limited U24304DL2018PTC339815 Delhi, Delhi, India
Nano Carbons Private Limited U24200MP2010PTC023568 Indore, Madhya Pradesh, India
S.S. Resins Private Limited U24299UP2007PTC032807 Kanpur, Uttar Pradesh, India
Omkar Fine Organics Private Limited U24119PY1988PTC000768 Pondicherry, Pondicherry, India
Herb Artizan Private Limited U15137KA2018PTC118294 Bengaluru, Karnataka, India
Hajra Medical Stores Private Limited U51397WB2001PTC093217 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pharmacompass before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pharmacompass: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Pharmacompass - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Pharmacompass pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Pharmacompass - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pharmacompass an active company?

Pharmacompass has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Pharmacompass financially healthy?

Pharmacompass has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.

Should I do business with Pharmacompass?

Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pharmacompass?

See the directors and ownership sections above for board and shareholding detail. 3 active director(s) are on record.

Does Pharmacompass have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Pharmacompass up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Pharmacompass?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.